The efficacies of cancer immunotherapy approaches are determined by their ability to induce tumor-specific cytotoxic T-lymphocytes (CTLs), which are major effector cells in tumor immunity. One approach to fighting cancer that is gaining popularity among tumor immunologists is immunization of cancer patients with autologous dendritic cells (DCs) loaded ex vivo with tumor-associated antigens (TAAs).
1)
DCs are unique professional antigen-presenting cells (APCs) capable of priming CTLs and helper T cells (Th) by presenting antigens via major histocompatibility complex (MHC) class I and II molecules, followed by co-stimulatory signals. In this regard, an essential event in the generation of effective tumor immunity is the efficient display of antigenic fragments by MHC class I molecules, which can prime and expand CTLs on the surface of manipulated DCs for immunization. MHC class I-presented peptides are usually derived from endogenous antigens synthesized by cells, including DCs. Antigens in the extracellular fluids do not gain access to the MHC class I-pathway in most cells and thus fail to be presented. DCs are capable of presenting exogenous antigens on MHC class I molecules in a process that is called "crosspresentation," and this process is markedly enhanced when the antigen is internalized by phagocytosis, 2) macropinocytosis, 3) or receptor-mediated endocytosis. 4, 5) Therefore, the development of a non-cytotoxic and efficient method to deliver antigens to the MHC class I-pathway in DCs is essential for improving the efficacy of DC-based cancer immunotherapy.
Immature DCs situated in peripheral tissues serve as sentinels to immunologic threats and actively internalize particulate antigens such as bacteria and viruses. 6, 7) Based on this characteristic, the particulate antigen delivery system is thought to be ideal for generating cross-presentation in DCs. We developed biodegradable nanoparticles comprising amphiphilic poly(g-glutamic acid) (g-PGA NPs) that can efficiently entrap various proteins. We previously reported that DCs loaded with g-PGA NPs containing entrapped antigens enhance antigen presentation via MHC class I molecules by delivering the antigens to the DC cytosol. 8, 9) It was unclear, however, whether g-PGA NPs affect DC maturation, and whether DCs loaded with TAA using g-PGA NPs more effectively induce TAA-specific CTL production and the anti-tumor response. Thus, in the present study, we investigated the characteristics and utility of g-PGA NPs as antigen delivery carriers in DC-based cancer immunotherapy.
MATERIALS AND METHODS

Mice and Cells
Female C57BL/6 mice (7 weeks of age) were purchased from Japan SLC Inc. (Hamamatsu, Japan). OT-I T cell receptor-transgenic mice specific for ovalbumin (OVA) (257) (258) (259) (260) (261) (262) (263) (264) presented by H-2K b and OT-II T cell receptortransgenic mice specific for OVA (323) (324) (325) (326) (327) (328) (329) (330) (331) (332) (333) (334) (335) (336) (337) (338) (339) presented by I-A b were purchased from Jackson Laboratory (Bar Harbor, ME, U.S.A.). Animal experimental procedures were performed in accordance with the Osaka University guidelines for the welfare of animals in experimental neoplasia. Isolation and cultivation of the murine bone marrow-derived DCs from C57BL/6 mice were performed according to the previously described method.
10) EL4 cells (murine thymoma cells; H-2K b ) and E.G7-OVA cells (OVA cDNA-transfectant of EL4 cells) were purchased from the American Type Culture Collection (Manassas, VA, U.S.A.). EL4 cells were cultured in complete RPMI1640 medium supplemented with 10% fetal bovine serum, 50 mM 2-mercaptoethanol, and antibiotics. E.G7-OVA cells were maintained in RPMI1640 medium containing 10% fetal bovine serum, 50 mM 2-mercaptoethanol, and 400 mg/ml G418.
Synthesis of Amphiphilic g-PGA and Preparation of g-PGA NPs Entrapping Proteins The g-PGA polymer was kindly provided by Meiji Seika Co., Ltd. (Tokyo, Japan). 11) The amount of protein entrapped in the g-PGA NPs was estimated using a DC protein assay kit (Bio-Rad Laboratories Inc., Hercules, CA, U.S.A,) after dissociation of g-PGA NPs using a 2% sodium dodecyl sulfate solution. The freeze-dried g-PGA NPs used in this study contained 220Ϯ20 mg entrapped protein/mg g-PGA. The size and z-potential of g-PGA NPs were measured using a Zetasizer 3000 HS (Malvern Instruments, U.K.). The g-PGA NPs used in this study were 250Ϯ50 nm in diameter, with a z-potential of Ϫ25Ϯ5 mV.
Evaluation of Cytotoxicity of g-PGA NPs to DCs DCs (2ϫ10 5 cells/well) were seeded in a 96-well flat-bottom culture plate and incubated with g-PGA NPs or soluble g-PGA polymers at 125, 250, or 500 mg g-PGA/ml in complete RPMI1640 medium for 3 or 24 h. Each well was washed twice with phosphate-buffered saline (PBS), incubated with 90 ml of complete RPMI1640 medium plus 10 ml of methyl thiazolyl tetrazolium (MTT, 5 mg/ml in PBS, Dojindo, Kumamoto, Japan) for 5 h at 37°C. Sodium dodecyl sulfate solution (100 ml of 20% (w/v) sodium dodecyl sulfate in 0.01 N HCl) was added to each well. After 4 h, cell viability was evaluated by measuring the mitochondrial-dependent conversion of the MTT to a colored formazan product. The absorbance (570 nm-test/630 nm-reference) was determined using a Spectra Max TM M5Y (Molecular Devices Inc., Tokyo, Japan).
Evaluation of Antigen Delivery Ability of g-PGA NPs to DCs DCs (10 6 cells/ml) were pulsed with FITC-OVA/g-PGA NPs or FITC-OVA at 0.1, 1, or 10 mg FITC-OVA/ml in complete RPMI1640 medium for 5 h at 4°C or 37°C. After washing twice with ice-cold PBS, cells were incubated with 0.25% trypsin in PBS for 30 min at 37°C. Cells were then fixed with 1% paraformaldehyde in ice-cold PBS. The mean fluorescence intensity (MFI) of cells was estimated by flow cytometry analysis using FACSCalibur TM (Becton Dickinson Co., Tokyo, Japan) with FlowJo TM software (Tree Star, Inc., Ashland, OR, U.S.A.).
Surface Phenotypic Analysis of g-PGA NP-Pulsed DCs DCs (10 6 cells/ml) were pulsed with 250 mg g-PGA NPs/ml in RPMI1640 medium for 3 h at 37°C. Mature DCs were prepared by cultivation in complete RPMI1640 medium containing 1 mg/ml of lipopolysaccharide (LPS) for 3 h. After washing twice with ice-cold PBS, cells were cultured in complete RPMI1640 medium for 24 h. Cells were harvested and incubated with anti-CD16/32 antibody (clone 2.4G2) to minimize nonspecific staining by the following immune reagents: biotinylated anti-CD40 (clone 3/23), anti-CD80 (clone 16-10A1), or anti-CD86 (clone GL1) monoclonal antibodies, and then developed with phycoerythrin-conjugated streptavidin. All immune reagents were purchased from BD Pharmingen (San Diego, CA, U.S.A.). Cells were analyzed for surface phenotype using FACSCalibur TM with FlowJo TM software. Measurement of Cytokine Secretion Levels from g-PGA NP-Pulsed DCs DCs (10 6 cells/ml) were pulsed with 62.5, 125, or 250 mg g-PGA NPs/ml in RPMI1640 medium for 3 h. After washing twice with ice-cold PBS, the cells were cultured in complete RPMI1640 medium for 72 h. The secretion levels of tumor necrosis factor (TNF)-a, interleukin (IL)-1b, and IL-12 in the culture supernatants were determined using enzyme-linked immunosorbent assay (ELISA) kits (BD Pharmingen).
Purification of CD4 ؉ or CD8 ؉ T Cells Spleens were isolated from OT-I or OT-II mice, and splenic T cells were enriched by nylon wool purification. OT-II CD4 ϩ or OT-I CD8 ϩ T cells were negatively isolated using CD4 ϩ or CD8 ϩ T cell isolation kits (Miltenyi Biotec Inc., Bergisch Gladbach, Germany) and an automagnetic-activated cell sorter (auto-MACS TM separator; Miltenyi Biotec Inc.) according to the manufacturer's instructions.
Mixed Leukocyte Reaction (MLR) Assay DCs (10 6 cells/ml) were pulsed with OVA/g-PGA NPs (100 mg OVA/ml, 500 mg g-PGA/ml), g-PGA NPs (500 mg g-PGA/ ml), or OVA (100 mg/ml) in RPMI1640 medium for 3 h. These DCs were used as stimulators and were suspended in complete RPMI1640 medium and seeded in 96-well flat-bottom culture plates at 250, 500, 1000, or 2000 cells/well. OT-II CD4 ϩ or OT-I CD8 ϩ T cells (10 4 cells/wells) were added as responders and the co-culture was maintained for 72 h. Cells were pulsed with 5Ј-bromo-2Ј-deoxy-uridine (BrdU) for the final 18 h of cultivation. T cell proliferation, based on the amount of BrdU incorporated during DNA synthesis, was determined using the colorimetric immunoassay, Cell Proliferation ELISA, BrdU (Roche Molecular Biochemicals, Meylan, France) according to the manufacturer's instructions. In addition, the secretion levels of interferon (IFN)-g or IL-4 in supernatants of 72 h co-cultivation were determined by ELISA; IFN-g (BD Pharmingen) or IL-4 (e-Bioscience, Inc., San Diego, CA, U.S.A.).
Immunization of Mice For the CTL assay and tumor challenge experiment, DCs (10 6 cells/ml) were pulsed with OVA/g-PGA NPs (100 mg OVA/ml, 500 mg g-PGA/ml), g-PGA NPs (500 mg g-PGA/ml), or OVA (100 mg/ml) in RPMI1640 medium for 3 h. After washing, cells were intradermally injected into the right flank of C57BL/6 mice at 3ϫ10 5 cells/50 ml. CTL Assay The CTL assay was performed according to the previously described method. 8) One week after DC-immunization, splenocytes isolated from immunized mice were re-stimulated with E.G7-OVA cells that had been inactivated using mitomycin C. Five days later, the splenocytes were collected as effector cells. The cytotoxic activity of the effector cells was assessed by a 51 Cr-release assay using E.G7-OVA or EL4 cells as targets, and was determined using the following formula: % of lysisϭ(counts of experimental 51 CrreleaseϪcounts of spontaneous 51 Cr-release)/(counts of maximum 51 Cr-releaseϪcounts of spontaneous 51 Cr-release)ϫ 100. The maximum or spontaneous release of 51 Cr was determined from cells treated with 2% Triton X-100 or the medium alone, respectively.
Tumor Challenge Experiment One week after immunization, mice received an intradermal injection of 2ϫ10 6 E.G7-OVA cells into the left flank. Tumor volume was calculated using the following formula: (tumor volume; mm 3 )ϭ (major axis; mm)ϫ(minor axis; mm) 2 ϫ0.5236. The mice were killed when one of the two axis measurements was greater than 20 mm.
RESULTS AND DISCUSSION
A critical feature antigen delivery carriers applied to DCbased cancer immunotherapy is the ability to introduce antigens into DCs while preserving DC viability and function. To clarify the uptake profile of g-PGA NPs by DCs, we analyzed the MFI of DCs pulsed with FITC-OVA/g-PGA NPs under conditions in which the nonspecific adsorption of g-PGA NPs to the cell surface was minimized by trypsinization. DCs incorporated FITC-OVA/g-PGA NPs in a dosedependent manner, whereas DCs incorporated little FITC-OVA alone at any dose (Fig. 1a) . Further, the pathway of uptake was confirmed to be endocytosis, because FITC-OVA/g-PGA NP-uptake levels were obviously reduced when energy metabolism was suppressed (4°C). Although DC viability was not markedly decreased by a 3 h-incubation with 100 to 500 mg/ml g-PGA NPs or soluble g-PGA polymers, 24 h-incubation with g-PGA NPs reduced DC viability in a dosedependent manner (Fig. 1b) . g-PGA NPs are likely more prone to accumulate on the cell surface at higher concentrations than soluble g-PGA polymers, thereby the activities to maintain homeostasis of cell were probably affected and it caused cytotoxicity. However, further studies are needed to define whether the environment of culture was changed and what affected cell viability. Therefore, g-PGA NPs in this study were used under the condition of a 3-h incubation and maximum dose of 500 mg/ml.
DCs mature in response to stimulation by bacteria-derived materials, such as LPS 12) or CpG motifs. 13 ) DC maturation is accompanied by an increase in the expression of co-stimulatory molecules and the production of T cell-stimulatory cytokines.
14,15) Co-stimulatory molecules have an essential role in antigen presentation, and cytokines function as cofactors for T cell activation and clonal expansion. In DC-based cancer immunotherapy, DC-maturation status correlates well with the induction efficacy of CTLs. 16, 17) We, therefore, investigated whether the application of g-PGA NPs influenced DC maturation in comparison with the LPS-inducible phenotype changes of DCs. The g-PGA NP-pulsed DCs exhibited increased CD40 and CD86 expression levels compared with mock DCs (Figs. 2a, b) . Furthermore, g-PGA NP-pulsed DCs showed enhanced secretion of TNF-a and IL-1b in a dose-dependent manner (Figs. 2d, e) . CD80 expression (Fig.  2c) and IL-12 secretion (Fig. 2f ) levels were not different from those of mock DCs. CD40 functions as a DC maturation stimulus, increasing the expression of CD86 and enhancing antigen presentation.
18) The interactions of CD86 with promotional receptors on T cells lead to enhanced T cell expansion and prolonged expression of the CD40 ligand. 19) Activated T cells secrete IL-2, and TNF-a and IL-1b further increase the secretion of IL-2. Together, these findings suggest that g-PGA NPs-pulsed DCs can be used to increase the clonal expansion of antigen-specific T cells by enhancing the phenotypic profile of co-stimulatory molecules and inflammatory cytokines.
CD8 ϩ or CD4 ϩ T cells recognize conjugates of respective epitope peptide fragments and MHC class I or class II molecules presented on DCs via T cell receptors, and thereby induce the antigen-specific CTLs or Ths, respectively. 20) To assess the T cell response induced by OVA-loaded DCs with g-PGA NPs, we performed an MLR assay using OT-I CD8 ϩ or OT-II CD4 ϩ T cells that specifically react to MHC class I or II antigen presentation of OVA epitope peptides, respectively. OVA/g-PGA NP-pulsed DCs, but not g-PGA NP-pulsed DCs, OVA-pulsed DCs, or mock DCs, showed significantly enhanced proliferation of OT-II CD4 ϩ and OT-I CD8 ϩ T cells. This finding is consistent with our previous report demonstrating that antigen delivery using g-PGA NPs into DCs enhances both MHC class I-and II-antigen presentation levels. 9) Although further research is needed to elucidate the relationship between the phenotype changes of DCs and the characteristics of g-PGA NPs, such as the components, kinetics in DCs, or physical properties, our findings suggest that the upregulation of antigen delivery and co-stimulation signal on DCs by g-PGA NPs promote antigen-specific T cell proliferation. The Ths are divided into two subsets, type 1-(Th1) and type 2-Ths (Th2). IFN-g-producing Th1s facilitate the induction of cellular immunity, whereas IL-4-producing Th2s suppress Th1-mediated cellular immunity and promote the induction of humoral immunity. 21 ) Interestingly, ϩ T cells co-cultured with OVA/g-PGA NP-pulsed DCs was significantly enhanced (Figs. 3c, d ). This result suggests that CD4 ϩ T cells differentiated into cellular immunity-dominant Th1s rather than the humoral immunitydominant Th2s in response to MHC class II antigen presentation of DCs loaded with antigens by g-PGA NPs. The CD8 ϩ T cells differentiate into IFN-g producing CTLs in response to MHC class I antigen presentation. The significant enhancement of IFN-g production was observed only in the supernatant of OT-I CD8 ϩ T cells co-cultured with OVA/g-PGA NP-pulsed DCs (Fig. 3e) . Accordingly, these findings raise the possibility that DCs loaded with antigens by g-PGA NPs induce antigen-specific CTLs via MHC class I antigen presentation and that they induce further clonal expansion and activation of antigen-specific CTLs via Th1 as an adjunct to MHC class II antigen presentation.
Finally, we investigated the efficacy of immunization with DCs loaded with antigens by g-PGA NPs on the antigen-specific CTL response and anti-tumor effect in vivo. Splenocytes derived from mice immunized with OVA/g-PGA NP-pulsed DCs exhibited potent cytotoxicity against E.G7-OVA cells compared with those derived from other groups (Fig. 4a) . These cytotoxic effects could be attributed to OVA-specific CTLs because cytotoxicity against EL4 cells after all immunizations was negligible. Furthermore, the E.G7-OVA tumor growth was significantly suppressed in mice immunized with OVA/g-PGA NP-pulsed DCs (Fig. 4b) . These effects were induced on the basis of the antigen delivery ability of g-PGA NPs, based on the fact that they were not observed in mice immunized with OVA-or g-PGA NP-pulsed DCs. These findings demonstrate that immunization with DCs loaded with antigens by g-PGA NPs induces anti-tumor effects that are reflected by the induction of antigen-specific CTLs in vivo.
In conclusion, the findings of the present study demonstrate that g-PGA NPs are excellent antigen delivery carriers for generating antigen-loaded functional DCs in DC-based cancer immunotherapy. Future studies are aimed at assessing the efficacy using TAAs, as well as analyzing the intracellular distribution of g-PGA NPs in DCs to enhance the ability to induce anti-tumor immunity. We believe that the DC-based vaccine system using g-PGA NPs as antigen delivery carriers will have broad applications to a number of vaccines designed to activate potent T cell responses, including vaccines for cancer or chronic viral diseases.
